5-Bromo-2-deoxyuridine activates DNA damage signalling responses and induces a senescence-like phenotype in p16-null lung cancer cells

Anti-Cancer Drugs

Volumn 18, Issue 9, 2007, Pages 1053-1068

  Masterson, Joanne C ^a   O'Dea, Shirley ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

5 bromo 2 deoxyuridine; DNA damage; Lung; Mitotic exit; Senescence

Indexed keywords

BETA GALACTOSIDASE; BROXURIDINE; CELL NUCLEUS ANTIGEN; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; PROTEIN P16; PROTEIN P21; PROTEIN P27; PROTEIN P53; PROTEIN P57;

ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL CYCLE G0 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL GRANULE; CELL GROWTH; CELL NUCLEUS; CELL PROLIFERATION; CELL SIZE; CELL TYPE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DNA DAMAGE; ENZYME ACTIVITY; GROWTH INHIBITION; HUMAN; HUMAN CELL; LUNG CANCER; MITOSIS RATE; MULTINUCLEAR CELL; NULL CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENESCENCE; SIGNAL TRANSDUCTION; UPREGULATION; WILD TYPE;

ANTIMETABOLITES, ANTINEOPLASTIC; BETA-GALACTOSIDASE; BROMODEOXYURIDINE; CELL CYCLE; CELL CYCLE PROTEINS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA DAMAGE; DNA, NEOPLASM; HUMANS; LUNG NEOPLASMS;

EID: 34548068534     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32825209f6     Document Type: Article

References (56)

1. Djordjevic B, Szybalski W. Genetics of human cell lines. III. Incorporation of 5-bromo- and 5-iododeoxyuridine into the deoxyribonucleic acid of human cells and its effect on radiation sensitivity. J Exp Med 1960; 112:509-531.
2. Greer S. Studies on ultraviolet irradiation of Escherichia coli containing 5-bromouracil in its DNA. J Gen Microbiol 1960; 22:618-634.
3. Ribas M, Korenberg JR, Peretti D, Pichiri G, Stockert JC, Gosalvez J, et al. Sister chromatid differentiation in 5-bromo-2′-deoxyuridine- substituted chromosomes: a study with DNA-specific ligands and monoclonal antibody to histone H2B. Chromosome Res 1994; 2:428-438.
4. Prados MD, Seiferheld W, Sandler HM, Buckner JC, Phillips T, Schultz C, et al. Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404. Int J Radiat Oncol Biol Phys 2004;58:1147-1152.
5. Anisimov VN. The sole DNA damage induced by bromodeoxyuridine is sufficient for initiation of both aging and carcinogenesis in vivo. Ann N Y Acad Sci 1994; 719:494-501.
6. Arlt MF, Casper AM, Glover TW. Common fragile sites. Cytogenet Genome Res 2003; 100:92-100.
7. Hsu TC, Somers CE. Effect of 5-bromodeoxyuridine on mammalian chromosomes. Proc Natl Acad Sci U S A 1961; 47:396-403.
8. Wojcik A, von Sonntag C, Obe G. Application of the biotin-dUTP chromosome labelling technique to study the role of 5-bromo-2′-deoxyuridine in the formation of UV-induced sister chromatid exchanges in CHO cells. J Photochem Photobiol B 2003; 69:139-144.
9. Sato S, Takizawa H, Inui N. Mouse strain differences in induction of micronuclei by base analogues and nucleosides. Mutat Res 1993; 301:45-49.
10. Call KM, Thilly WG. 5-Azacytidine inhibits the induction of transient TK-deficient cells by 5-bromodeoxyuridine. A novel hypothesis for the facilitation of hypermethylation by 5-bromodeoxyuridine. Mutat Res 1991; 248:101-114.
11. Hsu TC, Somers CE. Properties of L cells resistant to 5-bromodeoxyuridine. Exp Cell Res 1962; 26:404-410.
12. Berry SE, Davis TW, Schupp JE, Hwang HS, de Wind N, Kinsella TJ. Selective radiosensitization of drug-resistant MutS homologue-2 (MSH2) mismatch repair-deficient cells by halogenated thymidine (dThd) analogues: Msh2 mediates dThd analogue DNA levels and the differential cytotoxicity and cell-cycle effects of the dThd analogues and 6-thioguanine. Cancer Res 2000; 60:5773-5780.
13. Berry SE, Loh T, Yan T, Kinsella TJ. Role of MutSalpha in the recognition of iododeoxyuridine in DNA. Cancer Res 2003; 63:5490-5495.
14. Littlefield JW, Gould EA. The toxic effect of 5-bromodeoxyuridine on cultured epithelial cells. J Biol Chem 1960; 235:1129-1133.
15. Abbott J, Holtzer H. The loss of phenotypic traits by differentiated cells, V. The effect of 5-bromodeoxyuridine on cloned chondrocytes. Proc Natl Acad Sci U S A 1968; 59:1144-1151.
16. Couwenhoven RI, Schwartz SA, Snead ML. Arrest of amelogenin transcriptional activation in bromodeoxyuridine-treated developing mouse molars in vitro. J Craniofac Genet Dev Biol 1993; 13:259-269.
17. Comi P, Ottolenghi S, Giglioni B, Migliaccio G, Migliaccio AR, Bassano E, et al. Bromodeoxyuridine treatment of normal adult erythroid colonies: an in-vitro model for reactivation of human fetal globin genes. Blood 1986; 68:1036-1041.
18. Githens S, Pictet R, Phelps P, Rutter WJ. 5-bromodeoxyuridine may alter the differentiative program of the embryonic pancreas. J Cell Biol 1976; 71:341-356.
19. Tapscott SJ, Lassar AB, Davis RL, Weintraub H. 5-bromo-2′- deoxyuridine blocks myogenesis by extinguishing expression of MyoD1. Science 1989; 245:532-536.
20. Younkin L, Silberberg D. Myelination in developing cultured newborn rat cerebellum inhibited by 5-bromodeoxyuridine. Exp Cell Res 1973; 76:455-458.
21. Gilchrist AJ, Meuser R, Turchinsky J, Shaw AR, Pasdar M, Dixon WT. Cell adhesion-mediated transformation of a human SCLC cell line is associated with the development of a normal phenotype. Exp Cell Res 2002; 276:63-78.
22. Feyles V, Sikora LK, McGarry RC, Jerry LM. Effects of retinoic acid and bromodeoxyuridine on human melanoma-associated antigen expression in small cell lung carcinoma cells. Oncology 1991; 48:58-64.
23. McBride S, Walsh D, Meleady P, Daly N, Clynes M. Bromodeoxyuridine induces keratin protein synthesis at a posttranscriptional level in human lung tumour cell lines. Differentiation 1999; 64:185-193.
24. Yen A, Forbes ME. c-myc down regulation and precommitment in HL-60 cells due to bromodeoxyuridine. Cancer Res 1990; 50:1411-1420.
25. Michishita E, Nakabayashi K, Suzuki T, Kaul SC, Ogino H, Fujii M, et al. 5-Bromodeoxyuridine induces senescence-like phenomena in mammalian cells regardless of cell type or species. J Biochem (Tokyo) 1999; 126:1052-1059.
26. Minagawa S, Nakabayashi K, Fujii M, Scherer SW, Ayusawa D. Early BrdU-responsive genes constitute a novel class of senescence-associated genes in human cells. Exp Cell Res 2005; 304:552-558.
27. Campisi J. Cellular senescence as a tumor-suppressor mechanism. Trends Cell Biol 2001; 11:S27-S31.
28. Lin S, Lin D, Riggs AD. Histones bind more tightly to bromodeoxyuridine-substituted DNA than to normal DNA. Nucleic Acids Res 1976; 3: 2183-2191.
29. Fasy TM, Cullen BR, Luk D, Bick MD. Studies on the enhanced interaction of halodeoxyuridine-substituted DNAs with H1 histones and other polypeptides. J Biol Chem 1980; 255:1380-1387.
30. Bick MD, Devine EA. Interaction of chromosomal proteins with BrdU substituted DNA as determined by chromatin-DNA competition. Nucleic Acids Res 1977; 4:3687-3700.
31. Schwartz SA, Snead ML. Bromodeoxyuridine-DNA interactions associated with arrest of rat odontogenesis in vitro. Arch Oral Biol 1982; 27:9-12.
32. Satou W, Suzuki T, Noguchi T, Ogino H, Fujii M, Ayusawa D. AT-hook proteins stimulate induction of senescence markers triggered by 5-bromodeoxyuridine in mammalian cells. Exp Gerontol 2004; 39:173-179.
33. Suzuki T, Michishita E, Ogino H, Fujii M, Ayusawa D. Synergistic induction of the senescence-associated genes by 5-bromodeoxyuridine and AT-binding ligands in HeLa cells. Exp Cell Res 2002; 276:174-184.
34. Kataoka M, Wiehle S, Spitz F, Schumacher G, Roth JA, Cristiano RJ. Down-regulation of bcl-2 is associated with p16INK4-mediated apoptosis in non-small cell lung cancer cells. Oncogene 2000; 19:1589-1595.
35. Isaka T, Nestor AL, Takada T, Allison DC. Chromosomal variations within aneuploid cancer lines. J Histochem Cytochem 2003; 51:1343-1353.
36. Croce MV, Colussi AG, Price MR, Segal-Eiras A. Identification and characterization of different subpopulations in a human lung adenocarcinoma cell line (A549). Pathol Oncol Res 1999; 5:197-204.
37. Di Micco R, Fumagalli M, Cicalese A, Piccinin S, Gasparini P, Luise C, et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 2006; 444:638-642.
38. Bartkova J, Rezaei N, Liontos M, Karakaidos P, Kletsas D, Issaeva N, et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 2006; 444:633-637.
39. Kurz DJ, Decary S, Hong Y, Erusalimsky JD. Senescence-associated (beta)-galactosidase reflects an increase in lysosomal mass during replicative ageing of human endothelial cells. J Cell Sci 2000; 113 (Pt 20): 3613-3622.
40. Sancar A, Lindsey-Boltz LA, Unsal-Kacmaz K, Linn S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem 2004; 73:39-85.
41. Webley K, Bond JA, Jones CJ, Blaydes JP, Craig A, Hupp T, et al. Posttranslational modifications of p53 in replicative senescence overlapping but distinct from those induced by DNA damage. Mol Cell Biol 2000; 20:2803-2808.
42. Maga G, Hubscher U. Proliferating cell nuclear antigen (PCNA): a dancer with many partners. J Cell Sci 2003; 116:3051-3060.
43. Lee MH, Yang HY. Negative regulators of cyclin-dependent kinases and their roles in cancers. Cell Mol Life Sci 2001; 58:1907-1922.
44. Coqueret O. New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment? Trends Cell Biol 2003; 13:65-70.
45. Huang X, Tran T, Zhang L, Hatcher R, Zhang P. DNA damage-induced mitotic catastrophe is mediated by the Chk1-dependent mitotic exit DNA damage checkpoint. Proc Natl Acad Sci U S A 2005; 102:1065-1070.
46. Pines J. Mitosis: a matter of getting rid of the right protein at the right time. Trends Cell Biol 2006; 16:55-63.
47. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A 1995; 92:9363-9367.
48. Zhou BB, Elledge SJ. The DNA damage response: putting checkpoints in perspective. Nature 2000; 408:433-439.
49. Chen QM. Replicative senescence and oxidant-induced premature senescence. Beyond the control of cell cycle checkpoints. Ann N Y Acad Sci 2000; 908:111-125.
50. Shay JW, Roninson IB. Hallmarks of senescence in carcinogenesis and cancer therapy. Oncogene 2004; 23: 2919-2933.
51. WAF1) to promote DNA repair. Cell 2003; 114:599-610.
52. Kip1): regulation and function of a haploinsufficient tumor suppressor and its misregulation in cancer. Exp Cell Res 2001; 264:148-168.
53. KIP2) control muscle differentiation at the myogenin step. Genes Dev 1999; 13:213-224.
54. Roninson IB. Tumor cell senescence in cancer treatment. Cancer Res 2003; 63:2705-2715.
55. Carvalhal AV, Marcelino I, Carrondo MJ. Metabolic changes during cell growth inhibition by p27 overexpression. Appl Microbiol Biotechnol 2003; 63:164-173.
56. CIP1) cause hypertrophy in LLC-PK1 cells. Kidney Int 1999; 56:494-501.